Fulcrum Therapeutics, Inc. FULC
3.72 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:01 PM EST
3.72 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
3.68 Day range 3.77
2.83 52-week range 15.74
- YTD
- -67.11%
- 1 year
- -51.50%
News
benzinga.com Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
benzinga.com Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage,…
benzinga.com UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following…
benzinga.com What's Going On With Fulcrum Therapeutics Stock On Thursday? Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.
benzinga.com This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analyst rating changes: Stifel and Piper Sandler downgrade FULC, while Truist, Jefferies downgrade TMHC and SARO respectively. See more views.
benzinga.com Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3 Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
benzinga.com Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3 Piper Sandler analyst Edward Tenthoff downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight and lowers the price target from $23 to $3.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4 Truist Securities analyst Gregory Renza downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $17 to $4.
benzinga.com Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4 Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and lowers the price target from $24 to $4.
benzinga.com CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, HPQ target raised, PRAX target cut, GNSS target raised, INTU target lowered, GH target raised, CRDO…
benzinga.com This Goldman Sachs Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday Wall Street analysts changed outlook on top names. Read about analyst rating downgrades on ED, FULC, INTU, NU.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $3 HC Wainwright & Co. analyst Andrew S. Fein downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Neutral and lowers the price target from $25 to $3.
benzinga.com Why Hewlett Packard Enterprise Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket HPE stock jumps 26.55% after reporting strong revenue growth. Top gainers are DXST, MRVL and more. Top losers are FULC, JZ, and more.
benzinga.com FULC Stock Crashes After Hours: What Investors Need To Know Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Fulcrum Therapeutics Launches Strategic Alternatives Review To Maximize Shareholder Value ― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage…
benzinga.com Fulcrum Discontinues Pociredir Program For Treatment Of Sickle Cell Disease After FDA Flags Concerns About Malignancy Risk From PRC2 Inhibitors On May 28, 2026, Fulcrum received meeting minutes from recent end-of-phase interactions with the FDA. The minutes reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD,…- benzinga.com Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript
benzinga.com Earnings Scheduled For April 27, 2026 
benzinga.com Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market trading after beating analyst estimates.
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
benzinga.com Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.- benzinga.com MedicAlert Foundation, SCDAA And Fulcrum Therapeutics Partner To Help Streamline And Expedite ED Care For People Living With Sickle Cell Disease Through Rapid Access To Patient-Specific Care Plans MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com What's Going On With Fulcrum Therapeutics Stock Tuesday? Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease patients.- benzinga.com Fulcrum Therapeutics Q4 EPS $(0.31), Inline Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
- benzinga.com Fulcrum Therapeutics Reports 12-Week Results From 20 Mg Dose Cohort Of Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Fulcrum Acquires Environmental Software Firm Wildnote; Financial Terms Not Disclosed Fulcrum, the AI-powered field process management and data collection platform, today announced it has acquired Wildnote, an environmental software company focused on regulatory compliance with field…
benzinga.com This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com JP Morgan Initiates Coverage On Fulcrum Therapeutics with Overweight Rating, Announces Price Target of $20 JP Morgan initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $20.- benzinga.com Truist Securities Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $18 Truist Securities analyst Gregory Renza maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $14 to $18.
- benzinga.com Fulcrum Therapeutics Prices $175M Public Offering of Common Stock And Pre‑Funded Warrants At $13.50 Fulcrum Therapeutics, Inc. ® ("Fulcrum") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare…
- benzinga.com B of A Securities Maintains Underperform on Fulcrum Therapeutics, Raises Price Target to $7 B of A Securities analyst Tazeen Ahmad maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Underperform and raises the price target from $6 to $7.
benzinga.com Toll Brothers Posts Mixed Q4 Results, Joins Almonty Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Fulcrum Therapeutics Announces Proposed $150M Public Offering Of Common Stock Fulcrum Therapeutics, Inc.® ("Fulcrum") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare…
benzinga.com Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results Fulcrum Therapeutics stock surges on Monday after releasing positive results from Phase 1b trial of pociredir in sickle cell disease.
benzinga.com Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump 
benzinga.com Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com RBC Capital Maintains Sector Perform on Fulcrum Therapeutics, Raises Price Target to $10 RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target from $7 to $10.- benzinga.com Cantor Fitzgerald Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $24 Cantor Fitzgerald analyst Kristen Kluska maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $15 to $24.
- benzinga.com Piper Sandler Reiterates Overweight on Fulcrum Therapeutics, Raises Price Target to $23 Piper Sandler analyst Edward Tenthoff reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price target from $16 to $23.
- benzinga.com HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $25 HC Wainwright & Co. analyst Andrew S. Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $18 to $25.
- benzinga.com Market-Moving News for December 8th FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Confluent Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket